

BIOWORLD™ TODAY

THE DAILY BIOPHARMACEUTICAL NEWS SOURCE

BIOTECH'S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS

VOLUME 26, NO. 223

[SPECIAL REPRINT](#)

NOVEMBER 20, 2015

In The Clinic

Pledpharma AB, of Stockholm, said that in December it expects to have the final minutes from an FDA meeting regarding Pledox (calmangafodipir), a candidate it's developing to prevent nerve damage caused by chemotherapy in cancer treatment.

The company said an end-of-phase II/pre phase III-meeting provided it with "constructive advice regarding the final trials." (See *BioWorld Today*, Nov. 19, 2015.)

©2015. REPRINTED WITH PERMISSION FROM THOMSON REUTERS.

For Sales Inquiries: http://ip-science.interest.thomsonreuters.com/Bioworld_Sales_Inquiry. NORTH AMERICA, Tel: +1-855-260-5607. Outside of the U.S. and Canada, Tel. +44-203-684-1797. For Customer Service Inquiries, NORTH AMERICA, Tel: +1-800-336-4474. Outside of the U.S. and Canada, Tel. +44-203-684-1796. Or email bioworld.support@thomsonreuters.com. Copyright ©Thomson Reuters. Reproduction is strictly prohibited. Visit our website at www.bioworld.com.



THOMSON REUTERS™